Repare Therapeutics Inc. (NASDAQ:RPTX) shares jumped 15% on Tuesday after the clinical-stage biotech firm announced an exclusive global licensing agreement with Swiss-based Debiopharm for its promising PKMYT1 inhibitor, lunresertib.
$10 million upfront payment to Repare
Up to $257 million in milestone payments
Single-digit royalties on future global sales
Debiopharm to assume full development control of lunresertib, including the MYTHIC study
The agreement expands on a prior collaboration signed in January 2024, focused on combining lunresertib with Debiopharm’s WEE1 inhibitor, Debio 0123—a duo seen as “highly synergistic” in driving tumor regression.
“This licensing deal allows us to focus on advancing our internal pipeline while enabling the continued progress of lunresertib in tough-to-treat tumors,” said Repare CEO Steve Forte.
With Debiopharm handling lunresertib, Repare will double down on its two internal assets:
RP-1664 (PLK4 inhibitor) in the LIONS Phase 1 trial
RP-3467 (Polθ ATPase inhibitor) in the POLAR Phase 1 trial
Both are expected to deliver clinical readouts in H2 2025.
Investors looking to track Repare's upcoming clinical milestones and financial metrics can explore its full financial statements and disclosures for a deeper view of pipeline monetization potential.
